Trials / Terminated
TerminatedNCT03829449
rVA576 (Coversin) Long Term Safety and Efficacy Surveillance Study
CONSERVE: rVA576 (Coversin) Long Term Safety and Efficacy Surveillance Study
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 15 (actual)
- Sponsor
- AKARI Therapeutics · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Long term management of patients with complement related diseases including Paroxysmal Nocturnal Haemoglobinuria and Atypical Haemolytic Uraemic Syndrome
Detailed description
Patients with diseases requiring complement inhibition who have previously taken part in Akari clinical trials and who wish to continue to receive rVA576 (Coversin) after their active participation in the parent trial has completed and patients treated under compassionate use or named patient arrangements who wish to continue on rVA576 (Coversin) therapy
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | rVA576 | The study population will consist of patients who have completed participation in clinical trials under other Akari protocols and who wish to continue to receive rVA576 (Coversin). |
Timeline
- Start date
- 2017-03-13
- Primary completion
- 2020-08-29
- Completion
- 2020-08-29
- First posted
- 2019-02-04
- Last updated
- 2025-04-10
- Results posted
- 2025-03-12
Locations
1 site across 1 country: Poland
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03829449. Inclusion in this directory is not an endorsement.